Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

BACKGROUND: We previously developed an immunotherapy treatment utilizing a cancer vaccine reagent KIF20A-66 in order to treat pancreatic cancer. KIF20A-66 is HLA-A24-restricted epitope peptide derived from KIF20A, a member of kinesin super family protein 20A that is significantly transactivated in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Asahara, Shingo, Takeda, Kazuyoshi, Yamao, Kenji, Maguchi, Hiroyuki, Yamaue, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225607/
https://www.ncbi.nlm.nih.gov/pubmed/24237633
http://dx.doi.org/10.1186/1479-5876-11-291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225607/
https://www.ncbi.nlm.nih.gov/pubmed/24237633
http://dx.doi.org/10.1186/1479-5876-11-291

Ejemplares similares